cleave kininogen substrates to produce potent vasoactive kinin peptides, which are involved in many biological processes including vasodilation, neurotransmission, pain production, inflammation, and cell proliferation (4). These cellular actions are modulated by two bradykinin receptors, B1 and B2 (26). The B2 receptor has a high affinity to kinin and mediates most of these biological processes. The B1 receptor has a weak affinity to intact bradykinin but a strong affinity to kinin's metabolites [des-Argg] bradykinin and [des-ArglO] kallidin ([des-ArglO,Lys] bradykinin). B1 seems to be absent in normal mammalian tissues but appears in pathological states such as inflammation and trauma (4).
The tissue kallikrein-kinin system is considered as a local hormonal system for the following reasons. First, the plasma concentration of kinins seldom reaches a sufficient level to cause acute decrease of blood pressure except under experimental conditions (5). Second, bradykinin has a short half-life (24). Third, circulating bradykinin does not have a long-term effect on arterial pressure, although intrarenal infusion of bradykinin could cause an acute elevation of renal blood flow (17). The tissue kallikrein-kinin system is a vasodepressor system (5). In the kidney, it works together with the renin-angiotensin vasopressor system to achieve the regulation of renal blood flow [calculated from renal perfusate flow (RPF)], glomerular filtration rate (GFR), sodium and water metabolism, and renin release (3, 22) . The balance between the vasodilators and vasoconstrictors in the kidney is important in blood pressure homeostasis.
The major vasopressor system is the renin-angiotensin system, in which all the key components are located in the kidney (6). In the kallikrein-kinin system, all the components were also identified in the kidney by immunohistochemistry or by in situ hybridization histochemistry, including the low-molecular-weight (LMW) kininogen (14,25), tissue kallikrein (7,14), kininases II (4, 30), and the bradykinin B2 receptor (12). The B2 receptor-like binding activity has been found in the rat mesangial cells in the glomeruli (11), which can mediate the bradykinin-induced contraction of these cells (2). However, whether the bradykinin B2 receptor is expressed in the renal glomeruli remains unknown. To understand the site of kinin action, we localized LMW kininogen and bradykinin B2 receptor mRNAs in the human kidney and in the endothelial cells of the blood vessels by in situ hybridization.
METHODS
Tissue preparation.
Fresh human tissues were collected within 6 h postmortem.
The specimens were processed routinely by embedding in paraffin after Formalin fixation. Two cases of autopsy and one case of biopsy specimens, which contains the normal portion of nephrectomy specimen of human renal carcinoma, were used for the study. They were cut into 5-urn sections, mounted onto gelatin-coated slides, and stored at room temperature before use. Riboprobe preparation.
A 209-bp human LMW kininogen cDNA fragment within exon 11 of the human kininogen gene (29) was generated from the human liver total RNA by reverse transcription-polymerase chain reaction (RT-PCR) with the upstream primer (5' GTCACCTAAGGTCCTGCGAG 3') and downstream primer (5' AGGCAGAGTGATAAAATGGC 3'). It was cloned into the pCRI1 vector (Invitrogen) at its PCR cloning site flanked by SP6 and T7 promoters.
A 321-bp human bradykinin B2 receptor cDNA fragment within exon 3 of the Bz receptor gene (18) was amplified from a genomic clone containing the human Bz receptor gene by PCR with the upstream primer (5' TTCCAGATCAGCACCTT 3') and downstream primer (5' TCACTGTCTGCTCCCTGC 3'). This fragment was cloned into the Sp73 vector at the Sma I site which is flanked by SP6 and T7 promoters.
These two constructs were confirmed by DNA sequencing and restriction enzyme mapping. To generate the sense and antisense riboprobes of these two genes, the two constructs were linearized, respec- tively, by different restriction enzymes on either side of their cDNA insert, and the fragments were purified by agarose gel electrophoresis.
"Run-off' transcripts were synthesized from 1 ug of linearized plasmid DNA using the SP6/T7 <DIG> RNA Labeling Kit (Boehringer-Mannheim). DNA templates were then removed by ribonuclease-free deoxyribonuclease digestion. The transcripts were ethanol precipitated and then dissolved in 100 ul diethyl bicarbonate-treated water. Concentrations were measured spectrophotometrically at 260 nm. The riboprobes were stored at -20°C before use.
In situ hybridization. The sections were deparaffinized with xylene and rehydrated through a graded ethanol series of decreasing concentrations (lOO%, lOO%, 95%, 70%, and 50%, 2 min for each) at room temperature.
Sections were treated with Proteinase K [5 ug/ml in 50 mM EDTA, 0.1 M tris(hydroxymethyl)aminomethane (Tris) hydrochloride; pH 8.01 at 37°C for 30 min, and cross-linked in acetic anhydride (0.25% in 0.1 M triethanolamine; pH 7.0) at room temperature for 10 min. Sections were dehydrated through a graded ethanol series of increasing concentrations (50%, 70%, 95%, 2 min for each) and air dried. Hybridization was performed by adding 100 ul of hybridization buffer (0.3 M NaCl, 20 mM Tris l HCl; pH 8.0, 5 mM EDTA, 50% formamide, 5~ Denhardt's solution, 10% dextran sulfate, 100 ug/ml herring sperm DNA, 100 ug/ml yeast tRNA, and 1.5 ug/ml riboprobe) to each slide and incubated in a humid chamber at 42°C overnight. After hybridization, the sections were washed at room temperature to a final stringency of 0.2X SSC (30 mM NaCl, 3 mM sodium citrate, pH 7.0). These sections were blocked with normal sheep serum and 0.3% Triton X-100 and then incubated with sheep anti-digoxigenin Fab fragments which were conjugated to alkaline phosphatase (nucleic acid detection kit, Boehringer-Mannheim).
The color reaction was performed by overnight incubation with 4.5 ul of nitroblue tetrazolium salt, 3.5 ul of 5-bromo-4-chloro-3-indolyl phosphate (X-phosphate; nucleic acid detection kit, BoehringerMannheim), and 0.24 mg of levamisole in 1 ml of bufir 3 (0.1 M Tris l HCl; pH 9.5, 0.1 M NaCl and 50 mM MgC12) at room temperature in the dark. Sections were dehydrated, treated with xylene, and mounted with Crystalmount.
Cell culture. The primary culture originated from human renal proximal tubular cells was established as described previously (10). Pooled normal human umbilical vein endothelial cells (HUVEC; Clonetics, San Diego, CA) were grown to confluence in endothelial cell growth medium (EGM; Clonetits). Human hepatoma cells HepG2 were cultured in F12 medium supplemented with 10% fetal calf serum. The colonic carcinoma cells T84 were cultured as described previously (1 RT-PCR Southern blot analysis of human bradykinin B2 receptor. Total RNA was isolated from cultured cells by guanidine-CsCl gradient centrifugation (9). The concentrations of the RNA samples were determined by spectrophotometric measurement at 260 and 280 nm. One microgram of total RNA was reverse transcribed in a 20-ul reaction mixture containing 4 ul of 5X RT buffer, 10 ul of 2 mM dNTP, 2 ul of 100 mM dithiothreitol, 10 U of Moloney murine leukemia virus reverse transcriptase (BRL), and 10 pmol of the 3' primer (5' GTTCAAGGAGGTCCAGACGG 3'). The RT reaction mixture was incubated at 37°C for 1 h to synthesize the first strand of cDNA. PCR was performed following reverse transcription by adding 5 ul of 10X PCR buffer, 2.5 U of Taq DNA polymerase, and 10 pmol of the 5' primer (5' GAA-CATCTTTGTCCTCAGCG 3') to the RT reaction mixture. PCR was run for 30 cycles in a thermal cycler with a denaturing phase of 1 min at 94"C, annealing phase of 2 min at 6O"C, and extension phase of 3 min at 72°C. One-third of RT-PCR products was subjected to Southern blot analysis using a nested oligonucleotide probe (5' GTACTCCTTCATG-GTCCGGAACACC 3'). The blotted membrane was washed twice in 6~ SSC at 60°C and exposed to Kodak X-ray film at -80°C.
Northern blot analysis of human LMW kininogen. A tissue blot of mRNAs from several human tissues [2 ug of poly(A)+ RNA in each lane] was hybridized following the recommended protocol (Clontech, Palo Alto, CA) with the nick-translated LMW kininogen cDNA probe corresponding to the sequence of the riboprobe. The blot was washed to a final stringency of 1X SSPE (1X SSPE is 0.15 M NaCl, 0.01 M NaH2POd, and 0.001 M EDTA, pH 7.4) with 0.1% sodium dodecyl sulfate at 65°C and was exposed to a X-ray film at -80°C with an intensifying screen for 3 h. The same blot was stripped and reprobed with a human cytoplasmic p-actin cDNA probe (Clontech) as a control for RNA quality and quantity.
RESULTS
Kininogen and B2 receptor riboprobes. Specific sense and antisense riboprobes for human LMW kininogen (209 bp) and bradykinin B2 receptor (321 bp) were prepared for cellular localization of their respective mRNAs in the human kidney. LMW kininogen and high-molecular-weight (HMW) kininogen mRNAs are derived from the transcript of the same gene by alternative splicing. The kininogen gene has 11 exons, in which the first 9 exons are common for HMW and LMW kininogen mRNAs. Exon 10 consists of the common sequence for the bradykinin and the unique sequence for HMW kininogen mRNA (29). Our kininogen riboprobe is specific for LMW kininogen, since it corresponds to a part of exon 11 of the kininogen gene. The B2 receptor riboprobe corresponds to a part of exon 3 of the human B2 receptor gene (18). The specificity of both probes was examined using the FASTA program.
Cellular localization of LMW kininogen mRNA. Figure 1 shows the distribution and localization of kininogen mRNAin the cortex of the human kidney, including the epithelial cells of the parietal and visceral (podocytes) layer of Bowman's capsule, distal tubules, and proximal tubules. It was also localized in the juxtaglomerular (JG) cells of the afferent arteriole and mesangial areas (Fig. lA) , as well as the endothelial cells (arrows) of the blood vessels and some kinds of circulating blood cells (Fig. 1B) . The distal tubules have the strongest staining in the cortex, and the proximal tubules have weak staining. No staining was observed in the interstitial cells and macula densa. Figure 1C shows a control section for kininogen using the sense riboprobe under the same conditions as the antisense riboprobe in the experiments. No signal was observed in the cortex of the control sections. Figure 2 shows localization of kininogen mRNA in the medulla of the human kidney using antisense or sense riboprobe. Figure 2A demonstrates the extensive staining in the collecting ducts and the epithelium of the thin and thick segments of Henle's loop of the medulla. Figure  2B shows that the control section did not stain with the kininogen sense riboprobe. Cellular localization of bradykinin B2 receptor mRNA. Figure 3 shows the distribution of B2 receptor mRNA in the cortex and medulla of the human kidney, including the mesangial areas, epithelial cells of parietal layer of Bowman's capsule, distal tubules, and proximal tubules. It was also localized in the JG cells (Fig. 3A) and the endothelial cells (arrows) of the blood vessels and some circulating blood cells (Fig. 3B) . Figure 3C shows the localization of Bz receptor mRNA in the medulla of the human kidney. Staining was observed in the collecting ducts and thin and thick segments of Henle's loop. No signals were observed in the podocytes, macula densa, and interstitial cells. The control section for B2 receptor using the sense riboprobe showed no staining in either the cortex or the medulla (data not shown).
RT-PCR Southern blot analysis of human bradykinin B2 receptor. To confirm the expression of the bradykinin B2 receptor gene in the endothelial cells of human blood vessels and renal proximal tubular cells, we identified the B2 receptor mRNA by RT-PCR Southern blot analysis with the B2 receptor-specific oligonucleotides (Fig.  4) . The results show the bradykinin Bz receptor mRNA in the human umbilical vein endothelial cells, renal proximal tubular cells, kidney, colonic carcinoma T84 cells, and prostatic carcinoma LNCaP cells. In contrast to kininogen, which expresses a high level in the human hepatoma HepG2 cells (data not shown), bradykinin Bz receptor mRNA was not detected in the HepG2 cells.
Northern blot analysis of human LMW kininogen. The specificity of the human LMW kininogen riboprobe was examined by Northern blot analysis. One band was obtained at 1.5 kb in the liver and kidney, corresponding to human LIVID kininogen mRNA, thus demonstrating the specificity of the LMW kininogen riboprobe (Fig.  5) . This result further indicates that the signals observed in the cortex and medulla of the human kidney we were able to show localization of kininogen and B2 receptor mRNAs in various regions of the kidney, which reveals the sites of kininogen and B2 receptor synthesis in this organ.
Our result, which shows the expression of kininogen and B2 receptor mRNAs in the mesangial areas, agrees with the findings of bradykinin receptor binding studies in the glomeruli (11). In vitro studies have shown that bradykinin can induce a dose-dependent contraction of rat mesangial cells, which can be inhibited by Bz receptor antagonist Hoe-140 (2). Therefore, these mesangial cells may be involved in controlling GFR by compensating RPF changes in the human kidney through their bradykinin Bz receptor (22). The results of these studies provide an anatomic support to the hypothesis that the kallikrein-kinin system may play a role in the control of renal glomerular function. Glomerular filtrate is formed in response to plasma hydrostatic pressure, which is opposed by the osmotic pressure of plasma colloids and the hydrostatic pressure of the fluids in Bowman's capsule. Synthesis of kininogen and B2 receptor in the epithelium of Bowman's capsule might be modulated in response to some minute changes in the filtrate, which in turn might regulate tubular functions. Identification of kininogen and B2 receptor mRNAs in the epithelium of Bowman's capsule demonstrates a potentially new site of action of the kallikrein-kinin system in the kidney. JG cells participate in the control of renal blood flow and maintenance of blood pressure. These cells not only synthesize and release renin into the circulation and the local fluid, but also synthesize other components of the renin-angiotensin system (16, 191 . In the kallikreinkinin system, we detected both kininogen and Bz receptor mRNAs in the JG cells of the afferent arterioles. In addition, tissue kallikrein mRNA was detected in and around these cells in human (7). The coexistence of these two systems in JG cells suggests that both of them may be involved in the control of RPF, probably through the efferent arteriolar vasoconstriction and
